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Transgenic miceAlzheimer's disease (AD) is the most common cause of dementia, and amyloid-β (Aβ) plaques and tau-
containing tangles are its histopathological hallmark lesions. These do not occur at random; rather, the neu-
rodegenerative process is stereotyped in that it is initiated in the entorhinal cortex and hippocampal forma-
tion. Interestingly, it is the latter brain area where the calcium-sensing enzyme hippocalcin is highly
expressed. Because calcium deregulation is a well-established pathomechanism in AD, we aimed to address
the putative role of hippocalcin in human AD brain and transgenic mouse models. We found that hippocalcin
levels are increased in human AD brain and in Aβ plaque-forming APP23 transgenic mice compared to con-
trols. To determine the role of hippocalcin in Aβ toxicity, we treated primary cultures derived from
hippocalcin knockout (HC KO) mice with Aβ and found them to be more susceptible to Aβ toxicity than con-
trols. Likewise, treatment with either thapsigargin or ionomycin, both known to deregulate intracellular cal-
cium levels, caused an increased toxicity in hippocampal neurons from HC KO mice compared to wild-type.
We found further that mitochondrial complex I activity increased from 3 to 6 months in hippocampal
mitochondria fromwild-type and HC KOmice, but that the latter exhibited a signiﬁcantly stronger aging phe-
notype than wild-type. Aβ treatment induced signiﬁcant toxicity on hippocampal mitochondria from HC KO
mice already at 3 months of age, while wild-type mitochondria were spared. Our data suggest that
hippocalcin has a neuroprotective role in AD, presenting it as a putative biomarker.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is the most common form of dementia,
affecting approximately 26 million people worldwide [1]. Histopa-
thologically, the AD brain is characterized by amyloid-β (Aβ) plaques
and tau-containing neuroﬁbrillary tangles in the brain [2,3]. At pres-
ent, there is no cure for this debilitating disease [1]. The hippocampus
is one of the earliest brain areas affected in AD, reﬂecting the fact that
it is the formation of new memories that is impaired at an early stageperiments. Y-AL and MG per-
discussed the data; Y-AL and
erials and input to discussion;
rain, participated in study de-
to discussion, and Y-AL and JG
entia Research (CADR) at the
ueensland, St Lucia Campus,
, j.goetz@uq.edu.au (J. Götz).
rights reserved.of disease [4]. Furthermore, this is a brain area known to be a major
target of excitotoxic damage, whereby neurons die because of exces-
sive stimulation of glutamate receptors [5].
Hippocalcin is a protein that is highly expressed in the hippocam-
pus [6]. It is a member of the neuronal-speciﬁc calcium sensor (NCS)
family of proteins, and by employing a calcium-activated myristoyl
switch it is translocated to the plasmamembrane upon binding of cal-
cium [7]. The expression pattern of hippocalcin differs from that of
other known members of the protein family, with hippocalcin being
mainly expressed in the hippocampus, while the other members are
also widely expressed in other brain regions [8]. This expression pat-
tern suggests that hippocalcin may have a unique function that is not
shared by the other family members.
Hippocalcin is important for the homeostasis of intracellular calci-
um levels. By studying the interaction between muscarinic acetylcho-
line receptors and NMDA receptors (NMDARs), it was found that
the stimulation of the muscarinic receptors caused long-term depres-
sion (LTD) of NMDAR-mediated synaptic transmission. This form of
LTD involved the release of Ca2+ from intracellular stores and was
expressed via the internalization of NMDARs. Interestingly, the data
1248 Y-A. Lim et al. / Biochimica et Biophysica Acta 1822 (2012) 1247–1257suggest that the molecular mechanism involves a dynamic interaction
between hippocalcin itself, the clathrin adaptor molecule AP2, the
postsynaptic density enriched protein PSD-95 and NMDARs. Speciﬁ-
cally, the authors of the study proposed that hippocalcin binds to
the SH3 domain of PSD-95 under basal conditions, and that it trans-
locates to the plasma membrane upon sensing Ca2+, thereby causing
PSD-95 to dissociate from NMDARs, permitting AP2 to bind and
initiating dynamin-dependent endocytosis [9]. Also, infusion of a
truncated mutant form of hippocalcin that lacks the Ca2+ binding do-
mains has been shown to prevent synaptically evoked LTD but had no
effect on long-term potentiation (LTP) [10]. To better understand the
function of this calcium sensor, knock-out mice have been generated
and shown to display memory deﬁcits in spatial recognition tasks,
further suggesting that the protein has a role in memory formation
[11]. Knock-out mice also show an impairment in the activation of
Raf conducted by the Ras signaling pathway [12]. Physiological incre-
ments of Ca2+ are sensed by hippocalcin with a K1/2 of 0.5 μM [13].
Hippocalcin has been found to exert a neuroprotective effect in vitro,
such as in the spinal cordmotor neuron-like cell lineNSC-34 or the neu-
roblastoma cell line Neuro-2a, by interacting with NAIP (neuronal apo-
ptosis inhibitory protein) or by promoting calcium extrusion [14,15].0
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Fig. 1. Western blot analysis of human AD and control (CTL) hippocampal samples (A). N
levels are comparable between AD and CTL brains (C), while there are signiﬁcantly highe
(D, E). Hippocalcin levels are signiﬁcantly higher in the AD brain compared to CTL (F). (*, pThere is also histopathological evidence for a role in neurodegeneration,
because of the protein's localization to Lewy bodies, insoluble aggre-
gates present in Parkinson's disease brains, thereby suggesting that
hippocalcin may play a role in the pathogenesis of this condition [16].
In Huntington's disease, on the other hand, hippocalcin levels are de-
creased [17]. Together, this data supports the notion that hippocalcin
is deregulated under neurodegenerative conditions.
The present study ﬁrstly aimed to determine the role of hippocalcin
levels in AD brain and in a mouse model with amyloid plaque forma-
tion.We further addressed the protein's role in Aβ toxicity using prima-
ry neuronal cultures that have been established from hippocalcin
knock-out and wild-type mice.
2. Materials and methods
2.1. Ethics statement
Human brain tissue was obtained from the Sydney Brain Bank, with
approval from theHuman Ethics Review Committee of the University of
New SouthWales.Written informed consentwas obtained fromdonors
or their next of kin for brain donation. The animal experiments wereL 
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Sydney (approval number K00/1-2009/3/4914).
2.2. Immunoﬂuorescence staining of transgenic mice
Six and 18 month-old transgenic APP23 mice [18] and age-
matched wild-type littermate controls were transcardially perfused
with 1× PBS, followed by separation of the cerebral hemispheres.
The left hemispheres were post-ﬁxed in 4% paraformaldehyde over-
night at 4 °C and the paraformaldehyde exchanged for 70% ethanol
on the next day. Brains were then processed in a Shandon Excelsior
processor (Thermo), followed by embedding in parafﬁn as described
[19]. Three μm sections were rehydrated step-wise before antigen
retrieval was performed in a microwave system (Milestone) in pre-
warmed Tris/EDTA at pH 9.0 for 7 minutes at 120 °C and allowed to
cool on the bench-top for 15 min. Sections were stained for Aβ withAPP23  
Fig. 2. Confocal ﬂuorescence analysis of 18 months-old Aβ-plaque-forming APP23 and wil
bodies directed against Aβ/APP (6E10; green), hippocalcin (Hc; red) and DAPI (nuclear). Ne
heads), while neurons that have high hippocalcin levels reveal no 6E10 staining within the6E10 (mouse, 1:500, Covance) and for hippocalcin (rabbit, 1:100,
[20]), and counterstained with DAPI (Invitrogen) to visualize the nu-
clei. Alexa-Fluor secondary antibodies (Alexa-Fluor 488 and Alexa-
Fluor 555, respectively, Invitrogen) were used for detection. Fluores-
cent pictures of the stained sections were taken on a Zeiss LSM 710
confocal microscope.
2.3. Protein extraction of transgenic mice
While the left hemisphere was used for immunoﬂuorescence, the
right hemisphere and the hippocampus were sub-dissected and snap
frozen in liquid nitrogen for Western blotting. Protein extraction was
performed on mouse hippocampal tissue using RIPA buffer (50 mM
Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate 1% Triton-X
with protease inhibitors). Tissue was sonicated on ice to obtain a ho-
mogeneous suspension. The lysates were centrifuged at 17,000 ×g forWT
6E10
Hc
Composite
DAPI
d-type littermate controls (WT). Parafﬁn-embedded sections were stained with anti-
urons that have high 6E10 reactivity show very low hippocalcin staining (white arrow-
limits of detection (grey arrowhead). Scale bar, 50 μm.
1250 Y-A. Lim et al. / Biochimica et Biophysica Acta 1822 (2012) 1247–125720 min at 4 °C. The supernatant was retrieved and protein levels were
determined using the Bradford assay. Samples were stored at−80 °C
until further use.
2.4. Human tissue and protein extraction
Frozen human hippocampal brain tissue from 6 AD and 6 age- and
gender-matched controls (age at death in years: AD 91±4, control
86±4; gender M/F: AD 4/2, control 2/4; post mortem delay (hrs):
AD 10±2, control 8±8) was homogenized in 1:10 w/v of a Tris
buffer solution (TBS) (2.5 mL of 20 mM Tris-CI, 5 mM EDTA, 0.02%
sodium azide) containing protease inhibitors (Complete Mini, Roche
Diagnostics). Homogenates were centrifuged at 17,000 ×g at 4 °C for
2 h and the supernatant was retrieved to obtain the Tris buffer-
soluble fraction. The pellet was re-suspended in TBS containing 2%
SDS (2.5 mL of 20 mM Tris-CI, 5 mM EDTA, 0.02% sodium azide, 2%
SDS) and protease inhibitors (Complete Mini, Roche Diagnostics)
and was centrifuged again at 17,000 ×g at 25 °C for 30 min to obtain
the SDS-soluble fraction, containing membrane-bound, intracellular0
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Fig. 3.Western blot analysis of 6 and 18 months-old APP23 transgenic and wild-type mice (A
wild-type and transgenic mice at both ages (B), an indication of a neurodegenerative state
while Aβ levels are signiﬁcantly higher in 18 month-old when compared to 6 month-old tr
of age in the transgenic animals (E). (*, pb0.05; **,pb0.01).proteins. The supernatant was retrieved and protein levels were de-
termined using the Bradford assay and stored at−80 °C until needed.
2.5. Western blotting
Forty μg of protein was separated on 10% Tris-Tricine SDS gels as
described previously to visualize Aβ [21]. Proteins were transferred
onto nitrocellulose membranes (Hybond, GE Healthcare). To enable
an accurate comparison between the different proteins of interest,
blots were cut at positions 55, 38 and 17 kDa using the protein mo-
lecular weight ladder (Fermentas, Catalogue number: SM-1811) as
reference, and blocked, in parallel, with 5% skim milk in 1× TBST
(Tris-Buffered Saline with 1% Tween 20) for an hour at room tem-
perature. Primary antibodies were diluted in 5% milk/TBST and in-
cubated overnight at 4 °C, using the following antibodies: 6E10
(directed against residues 1-16 of Aβ, 1:1000, Covance), GAPDH
(1:5000, Millipore), NeuN (1:1000, Millipore) and Hippocalcin
(1:1000) [20]. Blots were washed 3 times with 1× TBST (5 minutes
wash each), and incubated with the respective alkaline phosphatase-0
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1251Y-A. Lim et al. / Biochimica et Biophysica Acta 1822 (2012) 1247–1257tagged secondary antibodies for 1 hour at room temperature. The blots
were again washed 3 times with 1× TBST (5 minute washes each),
after which they were developed with Immobilon Chemiluminescent
Alkaline Phosphatase substrate (Millipore), and detected using the
VersaDoc Model 4000 CCD camera system (BioRad). Densitometric
analyses were performed using the ImageJ software (NIH).
2.6. Primary cultures
Primary cultures were prepared from embryonic day 16 (E16)
hippocalcin-knockout and wild-type mice as described previously
[22]. In brief, hippocampi and cortices were dissected and trypsinized
in Hank's balanced salt solution (HBSS) with 0.0008% DNase (w/v).
The preparation was gently shaken and centrifuged at 720 ×g for
3 minutes at room temperature to allow the brain pieces to settle at
the bottom of the tube. The supernatant was aspirated and the
remaining brain tissue was triturated 30 times in plating media (10%
FBS in DMEM). Cell numbers were determined using a Neubauer
haemocytometer (Marienfeld, Germany). 50,000 cells were plated per
well. Cultures were placed in a 5% CO2 incubator at 37 °C for 2 h to
allow the cortical neurons to adhere to the poly-lysine pre-coated 48-
well plates, after which the plating mediumwas removed and replaced
with Neurobasal medium supplemented with 1% (v/v) B27 supple-
ments (Gibco), 0.01% (v/v) 200 mM L-glutamine (Gibco) to minimize
growth of microglia and astrocytes. Cultures were grown for 10 days
in vitro (DIV) before treatment.0
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Fig. 4.MTT assay to determine cell viability after thapsigargin treatment of wild-type and hip
were the most resistant to thapsigargin toxicity and treatment with 0.1 μM and 1.0 μM thap
trations, hippocalcin knock-out hippocampal cultures had a survival rate of 33% and 30%. (B)
with cell survival rates all at around 20% (C,D). (**,pb0.01; ***, pb0.001, #, pb0.05).2.7. Treatment and cell viability of primary cultures
After 10 days in vitro (DIV), primary hippocampal and cortical
neurons were treated with different concentrations of thapsigargin
(Sigma), ionomycin (Sigma), Aβ42 (Bachem) or DMSO for 4 days. In
addition, primary cultures were treated with Aβ42. Cell viability
was assayed using MTT as described previously [23]. Background ab-
sorbance was subtracted from raw MTT absorbance readings and
resulting values were normalized against DMSO vehicle treatments
as described [24].
2.8. Mitochondrial analysis
Hippocampi (left and right hippocampi pooled for each animal)
and cortices were dissected from ﬁve mice per group (3 months-old
wild-type, 3 months-old hippocalcin knockout, 6 months-old wild-
type, and 6 months-old hippocalcin knock-out). Mitochondria were
isolated as described [25], and the protein concentration determined,
followed by pooling of the samples within a group to obtain sufﬁcient
material for the mitochondrial analysis. Then, 100 μg of mitochondria
in a volume of 20 μl was used for measurement of complex I activity
per experiment. At least three measurements were performed per
group. 100 μg of isolated mitochondria were solubilized in n-dodecyl
β-D-maltoside (0.1 mg). NADH:hexaammineruthenium(III)-chloride
(HAR) activity was measured at 30 °C in a buffer containing 2 mM
Na+/MOPS, 50 mM NaCl, and 2 mM KCN, pH 7.2, using 2 mM HAR0.1µM Thap 1.0µM Thap DMSO
0.1µM Thap 1.0µM Thap DMSO
WT Hip
WT Cx
KO Hip
KO Cx 
pocalcin knock-out cortical and hippocampal cultures. Wild-type hippocampal cultures
sigargin resulted in cell viabilities of 75% and 50% respectively (A). At the same concen-
Wild-type and hippocalcin knock-out cortical cultures were not signiﬁcantly different,
1252 Y-A. Lim et al. / Biochimica et Biophysica Acta 1822 (2012) 1247–1257and 200 μM NADH as substrates to estimate the complex I content.
To determine NADH-ubiquinone oxidoreductase activity, 100 μM n-
decylubiquinone (DBQ) and 100 μM NADH were used as substrates
and 5 μM rotenone as inhibitor, as described previously [26]. Oxida-
tion rates of NADH were recorded with a Shimadzu Multi Spec-1501
diode array spectrophotometer (ε340-400 nm=6.1 mM–1 cm−1).
Complex I activity was normalized to the complex I content of the mi-
tochondrial preparation and is given as DBQ/HAR ratio. To determine
the effect of Aβ, 2.2μl of ﬁbrillar Aβ42 preparation (ﬁnal assay con-
centration 5 μM) were added to the mitochondrial suspension and
incubated for 15 min on ice [27], before measurement of complex I
activity.
3. Results and Discussion
3.1. Hippocalcin levels vary with Aβ levels in human hippocampal brain
samples
Hippocalcin is a neuronal protein that is highly expressed in the
hippocampus [20]. Since this brain area is one of the brain structures
where the degenerative process is initiated in AD, we performed
Western blotting on protein extracts obtained from the human AD
hippocampus and age- and gender-matched control brain samples
(Fig. 1A). NeuN was used for quantiﬁcation as it correlates well with
the number of viable neurons (Fig. 1B) [28,29]. Western blotting
showed that levels of Aβ monomers and trimers were signiﬁcantly
higher in AD brains than controls (both pb0.05) (Fig. 1D, E), while
APP levels did not differ (p=0.08) (Fig. 1C), as previously observedA
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Fig. 5.MTT assay for cell viability after ionomycin treatment of wild-type (A, C) and hippoca
ment was not toxic to all neuronal preparations except for hippocalcin knock-out hippocam[30]. NeuN levels were signiﬁcantly lower in AD brains compared to
controls, reﬂecting the neuronal loss that characterizes AD (pb0.05)
[31]. Interestingly, levels of the neuronal protein hippocalcin [14,32]
were signiﬁcantly increased in AD brains compared to controls,
suggesting that the calcium sensor is up-regulated in those neurons
that survive the degenerative process, possibly as a protective mech-
anism against Aβ toxicity (pb0.05) (Fig. 1F). Together, our ﬁndings
indicate that the surviving neurons in AD brains have higher levels
of hippocalcin than neurons in healthy control brains. This suggests
a neuroprotective role for hippocalcin.
3.2. Levels of hippocalcin and Aβ are inversely correlated in APP23 mouse
brain
To validate the ﬁndings for hippocalcin observed in human tissue
in mice, we investigated the expression of hippocalcin in Aβ-plaque-
forming APP23 mice, an established AD mouse model [18]. The
APP23 strain expresses human APP together with the AD pathogenic
KM670/671NL double mutation (Swedish mutation). In these mice,
Aβ levels increase with age, and by around 6 months, Aβ plaque
formation is initiated. To correlate the hippocampal expression of
hippocalcin with Aβ, we analyzed 6 and 18 month-old transgenic
mice and wild-type littermate controls. We ﬁrst co-stained sagittal
sections with antibody 6E10 for Aβ and a hippocalcin-speciﬁc antise-
rum [20], and counterstained with DAPI to visualize the nucleus.
6E10 shows some cross-reactivity with full-length APP. The data re-
veal an inverse relationship between the Aβ/APP pathology and the
staining intensity for hippocalcin in APP23 hippocampal neurons. AtB
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1253Y-A. Lim et al. / Biochimica et Biophysica Acta 1822 (2012) 1247–12576 months, there was no 6E10 reactivity detectable (data not shown).
At 18 months, confocal microscopy revealed that wild-type CA1 pyra-
midal neurons had a uniformly strong reactivity for hippocalcin, while
in the APP23 hippocampus, there were two types of cells revealing an
inverse relationship between hippocalcin and 6E10 reactivity: there
were CA1 neurons that showed a strong hippocalcin reactivity and
none for 6E10 (grey arrowhead), and others that showed a strong
staining for 6E10 reactivity that were hippocalcin-negative (white ar-
rowheads) (Fig. 2). Intracellular Aβ has previously been correlated
with neuronal loss and found to be a good predictor for synaptic dys-
function and neuronal loss in AD [33,34]. Further, increased levels
of intracellular calcium were found to promote the formation of olig-
omeric forms of Aβ [35,36]. Interestingly, increased calcium levels
also promote the aggregation of α-synuclein that forms aggregates
in Parkinson's disease [37]. As it is established that hippocalcin pro-
tects neurons by enhancing calcium extrusion [14], the inverse rela-
tionship in hippocampal neurons expressing hippocalcin and 6E10
reactivity suggests that Aβ may cause reduced levels of the calcium
sensor hippocalcin preventing it from conferring neuroprotection.
In APP23 mice there are less plaques in the hippocampal formation
compared to the cortex, despite comparable expression levels in the
two brain areas [38]; whether this is because hippocalcin confers ini-
tial protection from plaque formation in the hippocampus, which is
not available to the cortex, where it is not expressed, remains to be
determined.A B
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signiﬁcant cell toxicity in all neuronal cultures. Treatment with Aβ42 at 0.5 μM led to a sur
neurons (B), and 63% in wild-type and hippocalcin knock-out cortical neurons (C,D). At 5 μM
#, pb0.05; ###, pb0.001).3.3. Hippocalcin protein levels in APP23 mice are higher than in
wild-type mice and increase with age
We next performed Western blotting on protein extracts obtained
from brains of 6 and 18 months-old APP23 transgenic mice and wild-
type littermate controls (Fig. 3A). We quantiﬁed levels of the neuro-
nal nuclear protein NeuN that reﬂects numbers of viable neurons
[28,29]. We found that NeuN levels were signiﬁcantly decreased in
APP23 transgenic compared to wild-type hippocampi at both 6 and
18 months of age (pb0.05 each) (Fig. 3B), reﬂecting the neurodegen-
erative state of the transgenic mice as determined previously [38,39].
APP levels in the APP23 hippocampus were not signiﬁcantly dif-
ferent for the two age groups (Fig. 3C), suggesting that they do not
change with aging. Aβ levels however were signiﬁcantly higher in
18 months-old APP23 transgenic mice compared to 6 month-olds
(Fig. 3D), as reported previously [40]. Since there was only a change
in Aβ, but not APP levels, any putative change in hippocalcin levels
can therefore be attributed to levels of Aβ rather than APP in these
mice. We found that hippocalcin levels were increased in 18- com-
pared to 6 months-old APP23 transgenic mice (pb0.05) (Fig. 3E),
in a pattern similar to that seen for Aβ. In contrast, hippocalcin
levels in wild-type controls did not show signiﬁcantly different
hippocalcin levels upon aging, further indicating that it is Aβ that
alters hippocalcin levels in the APP23 mice. Together with the immu-
nohistochemical data, this indicates that hippocalcin is altered in APP.5µM Aβ42 5.0µM Aβ42 DMSO
.5µM Aβ42 5.0µM Aβ42 DMSO
# WT Hip
WT Cx
KO Hip
KO Cx
nock-out (B,D) cortical (C,D) and hippocampal cultures (A,B). Aβ42 treatment induced
vival rate of 65% in wild-type hippocampal neurons (A), 54% in hippocalcin knock-out
, cell viabilities of all neuronal preparations were below 50%. (**,pb0.01; ***, pb0.001;
1254 Y-A. Lim et al. / Biochimica et Biophysica Acta 1822 (2012) 1247–1257mutant mice. This may suggest that neurons upregulate hippocalcin
to counteract the toxicity of Aβ as addressed below.
3.4. Hippocalcin knock-out neurons are more sensitive to calcium
deregulation than wild-type neurons
Numerous studies indicate a neuroprotective effect of calcium-
binding proteins (Ca2+ binding proteins) in neurodegenerative dis-
eases [41]. To better understand the putative neuroprotective role of
hippocalcin in calcium deregulation, primary cortical and hippo-
campal neuronal cultures were obtained from embryonic day 16
(E16) hippocalcin-knockout ([11] and wild-type mice. After 10 days
in vitro (DIV), the neurons were treated with varying concentrations
of thapsigargin (Fig. 4) and ionomycin (Fig. 5), both of which are
known to raise intracellular calcium levels although via distinct mech-
anisms [42,43]. Thapsigargin has been shown to raise the intracellular
calcium concentration by preventing cells from directing calcium into
the endoplasmic reticulum, thereby depleting intracellular calcium
stores [44]. Ionomycin affects extracellular calcium transport into
cells by increasing the calcium permeability of the plasma membrane
[45].
We compared hippocampal and also cortical cultures from wild-
type and hippocalcin knockout mice and treated them for 2 days
with the two compounds, followed by an MTT assay to assess cell vi-
ability. Treatment with 0.1 μMof thapsigargin revealed that wild-type
hippocampal neurons were the most resistant, with a survival rate of
about 75% (Fig. 4A). Wild-type cortical neurons had a survival rate of
less than 25% (pb0.01 versus non-treated counterparts). Hippocalcin
knock-out hippocampal and cortical neurons had a survival rate of
33% and 21%, respectively (pb0.01 versus non-treated counterparts)
(Fig. 4B–D). At 1.0 μM thapsigargin, cell viability of wild-type hippo-
campal neurons was about 50% (Fig. 4A), while for the knockout hip-
pocampal neurons, it was 30% (Fig. 4B–D). We did not ﬁnd signiﬁcantA B
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Fig. 7. MTT assay for cell viability after hydrogen peroxide (H2O2) and staurosporine (stau)
pocampal cultures (A,B). Cell viabilities of hippocalcin knock-out neurons were not signiﬁ
staurosporine, indicating that hippocalcin knock-out neurons are not selectively sensitive tdifferences in cell viability between wild-type and hippocalcin knock-
out cortical cells (between 20 and 30%) (Fig. 4C, D), which is not
surprising since hippocalcin is only expressed at very low levels in
the cortex [8]. Together, our ﬁndings reveal that hippocalcin protects
hippocampal neurons from the toxic effects exerted by thapsigargin.
To further assess the neuroprotective effects of hippocalcin,
primary hippocampal and cortical cultures from hippocalcin knock-
out and wild-type mice were treated with different concentrations
of ionomycin. Treatment with 0.1 μM ionomycin was not toxic to
any treatment groups (Fig. 5). However, at 1 μM, ionomycin was
toxic only to hippocalcin-knockout hippocampal neurons (pb0.001)
(Fig. 5B), while wild-type cortical neurons, as well as hippocalcin
knock-out hippocampal and cortical neurons were spared (Fig. 5A,
C, D). Together, this supports the notion that calcium homeostasis is
critical in determining neuronal survival. Our data indicate that
hippocalcin may play an important role in the maintenance of calci-
um homeostasis in the hippocampus.
3.5. Hippocalcin knock-out neurons are more sensitive to Aβ toxicity
Since hippocalcin levels are consistently up-regulated in human
AD as well as in transgenic APP23 mice, the putative neuroprotective
role of hippocalcin in Aβ toxicity was further investigated by deter-
mining cell viability of primary hippocampal and cortical cultures
from hippocalcin knockout and wild-type mice, after treatment with
varying concentrations of Aβ (Fig. 6).
This revealed a dose-dependent toxicity and cell viability that
was decreased for all cell types by treating the cultures with Aβ con-
centrations between 0.5 and 5 μM (pb0.05 to pb0.001) (Fig. 6A, C,
D), except for the hippocalcin knock-out hippocampal neurons, for
which at 0.5 μM of Aβ, the cells already revealed the lowest viabil-
ity of all cultures (Fig. 6B). At 0.5 μM Aβ, the survival rate of all cell
cultures was around 65% (Fig. 6A, B, D), except for hippocalcin-10 µM
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Fig. 8. Mitochondrial complex I activity (DBQ/HAR ratio) in the hippocampus (A,C)
and cortex (B,D) from 3- and 6 months-old wild-type (WT) and hippocalcin knock-out
(HC KO)mice. Complex I activity increased from 3 to 6 months in hippocampalmitochon-
dria from WT as well as HC KO mice, but HC KO mitochondria exhibited a signiﬁcantly
stronger aging phenotype than WT mice (A) (Two-way ANOVA: aging effect p=0.0003,
KO effect p=0.0446). In cortical mitochondria (B) complex I activity decreased from 3
to 6 months in both mice groups. Again, HC KO mitochondria exhibited a signiﬁcantly
stronger aging phenotype than inWT (Two-way ANOVA: aging effect p=0.001, KO effect
p=0.002). Aβ42 treatment induced signiﬁcant toxicity on hippocampal mitochondria
from HC KO mice already at 3 months of age (C), whereas WT mitochondria were
spared (C). Sensitivity to Aβ42 treatment was signiﬁcantly increased at 6 months (C,D).
A-D: (*p>0.05; **,pb0.01; ***, pb0.001; +pb0.05; ++pb0.01).
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This indicates that hippocalcin-knockout hippocampal neurons are
more susceptible to Aβ toxicity. However at 5 μM Aβ, the survival
rates of all cell types were around 45%, obliterating any neuro-
protective effects of hippocalcin.
Aβ is known to exert its toxicity via a myriad of mechanisms
[46–48]. To determine whether the toxicity observed after exposure
to Aβ is speciﬁc to Aβ rather than being a general consequence of
cell death, wild-type and hippocalcin-knockout neurons were also
exposed to varying concentrations of hydrogen peroxide as a source
of oxidative stress, as well as staurosporine, a non-selective protein
kinase inhibitor that exerts toxicity by interfering with many toxicity
pathways [49]. Importantly, for both treatments, the viability of both
hippocalcin knock-out hippocampal and cortical cells did not differ
from their wild-type counterparts (Fig. 7), indicating that the suscep-
tibility of hippocalcin knock-out hippocampal neurons to Aβ toxicity
is speciﬁc. Together, these data suggest that hippocalcin has a critical
function at an early stage of Aβ-induced toxicity in AD.
3.6. Hippocalcin knock-out neurons show an age-dependent
deregulation of complex I activity and vulnerability to Aβ insult
Since MTT measurements (Figs. 4–7) are an indicator of mito-
chondrial health [24,50], we next determined whether mitochondrial
functions are impaired in the hippocalcin knock-out hippocampus.
We found that between 3 and 6 months of age, mitochondrial com-
plex I activities go up in both wild-type and hippocalcin knock-out
hippocampi (Fig. 8A), whereas an age-dependent decline is present
in wild-type and hippocalcin knock-out cortices (Fig. 8B). Of note,
in both brain regions the lack of hippocalcin induced a stronger
aging phenotype. At 3 months of age, the basal activity of complex I
is about 10-fold higher in cortical compared to hippocampal mito-
chondria in wild-type, but only about 3-fold higher in hippocalcin
knock-out mice demonstrating a deregulation of mitochondrial activ-
ity. At 3 months, hippocampal wild-type mitochondria showed no
sensitivity for Aβ, in contrast to hippocampal hippocalcin knock-out
mitochondria where Aβ induced a signiﬁcant reduction of complex I
activity (Fig. 8C). No sensitivity to Aβ could be detected in cortical
mitochondria from 3 months-old wild-type as well as hippocalcin
knock-out animals (Fig. 8D), in contrast to wild-type mitochondria
which were spared. At 6 months sensitivity to Aβ was strongly
enhanced in hippocampal as well as in cortical mitochondria from
hippocalcin knock-out mice (Fig. 8C, D). We conclude that the highest
sensitivity to Aβ, i.e. reduction of complex I activity, is most pro-
nounced in the hippocampus of hippocalcin knock-out mice where
usually the highest level of hippocalcin is found, further supporting
the notion that hippocalcin has a critical function in neuroprotection
against Aβ toxicity.
4. Conclusions
Alzheimer's disease (AD) is characterized by widespread exci-
totoxicity, especially in the hippocampus, one of the brain structures
known to degenerate earliest in AD [51]. Hippocalcin is a neuron-
speciﬁc calcium sensor protein that is highly expressed in the hippocam-
pus and has previously been suggested to be neuroprotective [14,32]. In
this study, we found that those hippocampal neurons that survive
the degenerative process in AD increase hippocalcin expression, indicat-
ing a neuroprotective attempt to promote neuronal survival. We also
found that hippocalcin levels were affected by Aβ levels. Our ﬁndings
suggest that neurons that are capable of up-regulating hippocalcin may
receive some protection, as indicated by our Western blot ﬁnding.
To investigate the neuroprotective role of hippocalcin, we had
treated embryonic neuronal primary cultures. In this experimental par-
adigm, hippocalcin-knock out hippocampal cultures showed signiﬁ-
cantly more toxicity in the presence of thapsigargin and ionomycin,indicating that hippocalcin plays an important neuroprotective role in
calcium-related neuronal injury in the hippocampus. This has signiﬁ-
cant implications for other calcium-related disorders such as stroke
and epilepsy [52]. Employing the same experimental system, we could
also show that hippocalcin confers neuroprotection against Aβ toxicity,
and this was reﬂected by the observed age-dependent changes inmito-
chondrial activities. Collectively, our study indicates that hippocalcin
1256 Y-A. Lim et al. / Biochimica et Biophysica Acta 1822 (2012) 1247–1257levels are deregulated by Aβ. They further present hippocalcin as a bio-
marker and possible therapeutic target for AD.
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